Abstract

Purpose Reduced physical activity in many chronic diseases is consistently associated with increased morbidity. Little is known about physical activity in sarcoidosis. The aim of this study was to objectively assess physical activity in patients with pulmonary sarcoidosis and investigate its relationship with lung function, exercise capacity, symptom burden, and health status.

Methods Physical activity was assessed over one week in 15 patients with pulmonary sarcoidosis and 14 age-matched healthy controls with a tri-axial accelerometer (ActivPal™) and the International Physical Activity Questionnaire (IPAQ). All participants underwent pulmonary function tests, 6-min walk test (6MWT) and completed the Fatigue Assessment Scale (FAS), Medical Research Council (MRC) Dyspnoea Scale and the King’s Sarcoidosis Questionnaire (KSQ).

Results Patients with sarcoidosis had significantly lower daily step counts than healthy controls; mean (SD) 5624 (1875) versus 10,429 (2942) steps ($p<0.01$) and a trend towards fewer sit-to-stand transitions each day ($p=0.095$). Only two patients (13%) self-reported undertaking vigorous physical activity (IPAQ) compared to half of healthy individuals ($p<0.01$). Daily step count was significantly associated with 6MWT distance in sarcoidosis ($r=0.634$, $p=0.01$), but not with forced vital capacity ($r=0.290$), fatigue ($r=0.041$), dyspnoea ($r=-0.466$) or KSQ health status ($r=0.099–0.484$). Time spent upright was associated with fatigue ($r=-0.630$, $p=0.012$) and health status (KSQ Lung scores $r=0.524$, $p=0.045$), and there was a significant correlation between the number of sit-to-stand transitions and MRC dyspnoea score ($r=-0.527$, $p=0.044$).

Conclusion Physical activity is significantly reduced in sarcoidosis and is associated with reduced functional exercise capacity (6MWD). Fatigue, exertional symptoms and health status were more closely associated with time spent upright and the number of bouts of physical activity, as compared to step counts. Further studies are warranted to identify the factors that determine different physical activity profiles in sarcoidosis.

Keywords Physical activity · Sarcoidosis · Exercise capacity

Introduction

Sarcoidosis is a multi-system disorder characterised by granulomatous inflammation. The lungs, skin, eyes and the musculoskeletal system are frequently affected [1, 2]. Patients...
with sarcoidosis often present with dyspnoea, fatigue and arthralgia [3, 4]. The exercise capacity of patients with sarcoidosis has been reported to be reduced, whether assessed with the 6-min walk test (6MWT) or cardiopulmonary exercise test [3–6]. A limitation of measures exercise capacity is that they provide a limited insight into the impact the disease has on activities of daily living [7].

Physical activity is impaired in many chronic diseases and is associated with increased morbidity and mortality [8–11]. Physical activity can be assessed objectively with validated accelerometers for prolonged periods [12, 13]. Recent studies have reported that patients with chronic respiratory disorders such as chronic obstructive pulmonary disease (COPD) [14–16] and idiopathic pulmonary fibrosis (IPF) [8, 9] have reduced physical activity. An important finding of these studies was that outcome measures of lung disease such as lung function, radiological imaging and health-related quality of life do not reflect the physical activity of patients [8, 16, 17]. Bahmer et al. recently reported the clinical predictors of walking physical activity (steps per day) in patients with mild sarcoidosis [18]. The step count was associated with exercise capacity but not with symptoms of physical fatigue [18]. This study, however, did not compare patients to a healthy control group and did not investigate the different types of physical activity in daily life since this was not available with the physical activity monitor they used [18].

There are physical activity monitors available that can measure different types of activity. The ActivPal™, a piezoelectric triaxial accelerometer, can assess daily step count, time spent in an upright posture, stepping time, and the number of sit-to-stand transitions. The reliability and validity of this monitor has been demonstrated in both healthy individuals and patients with COPD [19–22]. The monitor has good reliability for step counts and stepping cadence at different walking speeds in both indoor and outdoor environments and during motor vehicle travel with a measurement error of <1% [19, 22].

In this pilot study, we aimed to investigate physical activity objectively with a triaxial accelerometer that can assess a range of activity in patients with sarcoidosis and healthy controls and investigate their relationships with exercise capacity, pulmonary function, fatigue and health status.

Methods

Participants and Clinical Characterisation

Consecutive participants with pulmonary sarcoidosis were recruited prospectively from a secondary care specialist clinic (King’s College Hospital, London, UK). The diagnosis of sarcoidosis and organ involvement were assessed by a multi-disciplinary team of clinicians and radiologists and established when clinical and histological features were consistent with those described in “A Case-Control Etiologic Study of Sarcoidosis” [23]. Chest radiographs were assessed by an experienced radiologist blinded to clinical details and reported according to the criteria described by Scadding [24]. Inclusion criteria were pulmonary involvement and stable condition in the past 3 months as judged by the clinician. Exclusion criteria were the presence of respiratory conditions other than sarcoidosis, co-morbidities which were considered to affect daily activities (cardiac disease, peripheral vascular disease, stroke, central and peripheral nervous disease other than sarcoidosis, osteoarthritis), upper respiratory tract infection within the last 4 weeks, active psychiatric disorder and the use of walking aids.

Healthy controls were recruited prospectively through advertisement. The healthy control inclusion criteria were normal spirometry and exclusion criteria were identical to those of sarcoidosis subjects. Demographics, anthropometric data and clinical characteristics were recorded. All participants gave informed written consent and the study was approved by the local research ethics committee (NRES Committee London Surrey Borders, 09/H0806/74).

Physical Activity Monitoring

Physical activity was assessed with the ActivPal™ (PAL Technologies Ltd, Glasgow, UK), a small, lightweight (35 × 53 × 7 mm, 15 g) piezoelectric triaxial accelerometer. The monitor was attached to participants’ upper thigh with hydrogel adhesion pads (PALstickies™, PAL Technologies Ltd, Glasgow, UK) and a Tegaderm™ transparent dressing (3M, St Paul, Minneapolis, USA). Accelerometry measurements were made at a sampling rate of 15 Hz and summarised into 15 s epochs, then downloaded and analysed using the manufacture’s software (ActivPal3™ version 7.1.18, PAL Technologies, Glasgow, UK).

Subjective Assessments

International Physical Activity Questionnaire

Participants were requested to complete the short version of the International Physical Activity Questionnaire (IPAQ) with the reference period being the last 7 days [25]. Craig et al. (2003) demonstrated that the IPAQ has acceptable reliability and validity when compared against accelerometers [25]. The short IPAQ assesses the duration and frequency of moderate (4–8 metabolic equivalents (MET)) and vigorous (>8 MET) physical activity and the time spent walking in the last 7 days [25]. Activity-specific scores were calculated as per scoring guidelines and were expressed as METs minutes per week and an overall weekly score. A higher score on the IPAQ indicates a higher level of physical activity [25].
Fatigue Assessment Scale

The Fatigue Assessment Scale (FAS) is a validated tool to assess fatigue in participants with sarcoidosis [26, 27]. The FAS has 10 items and a score ranging from 10 to 50, where a score greater than 22 indicates fatigue [27].

MRC Dyspnoea Scale

Participants were asked to report the impact of breathlessness on their daily activities using the Medical Research Council (MRC) dyspnoea scale (score range 1–5) [28].

Health Status: King’s Sarcoidosis Questionnaire

The King’s Sarcoidosis Questionnaire (KSQ) was used to assess the health status of the participants with sarcoidosis [29]. The KSQ is a self-administered questionnaire which has been validated for use in subjects with sarcoidosis and has recently been utilised in clinical trials [29, 30]. The KSQ comprises of 29 questions which are divided into 5 modules: General Health (10 items), Lung (6 items), Skin (3 items), Eye (7 items) and Medications (3 items). The response to each item is recorded on a 7-point Likert scale. Participants completed the General Health and Lung modules and remaining modules as applicable. KSQ Scores range from 0 to 100, where 0 is severe health status impairment and 100 is no impairment [29].

Lung Function and Exercise Capacity

Spirometry was measured according to the Association for Respiratory Technology and Physiology and the European Respiratory Society guidelines (Jaeger MS-PFT Analyser Unit with Lab Manager Software version 5.32.0) [31, 32]. Participants underwent the 6-min walk test (6MWT) as per the European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines [33].

Protocol

Participants completed the questionnaires, spirometry and 6MWT prior to the application of the activity monitor. Participants were instructed to wear the activity monitor for 8 consecutive days commencing on a Monday, removing it briefly only for personal hygiene. An illustrated manual with key information and guide for attaching the activity monitor and training was provided to participants. Participants were given a diary to record times spent sleeping and when the activity monitor was detached. Activity monitor data from the first and final day was excluded in the analysis since this included activity related to the study hospital visits. Therefore, activity data from 6 days, which included 4 weekdays and 2 weekend days were analysed. When the activity monitor was attached for < 8 h, data for that day were discarded.

Statistical Analysis

Data were analysed using Prism® Version 7.0c for macOS version 10.13.3 (GraphPad Software; San Diego, California, USA). The distribution of data was assessed using the D’Agostino and Pearson test. Parametric data were expressed as mean (standard deviation, SD) whereas non-parametric data were expressed as median (interquartile range, IQR). Parametrically distributed data were analysed with independent unpaired Welch’s t tests to compare sample means, whereas comparison of non-parametric data was carried out using the Mann–Whitney U test. Chi-squared test was utilised for categorical data. Correlations between variables were analysed with Pearson’s correlation coefficient (r) for parametric data and Spearman’s correlation coefficient (ρ) for non-parametric data. A p value of less than 0.05 was considered statistically significant.

A formal sample size was not calculated since this was a pilot study. A recent study investigating physical activity was able to detect significantly reduced physical activity in 15 participants with fibrotic idiopathic interstitial pneumonia [8].

Results

Participant Characteristics

Fifteen consecutive participants with pulmonary sarcoidosis and fourteen healthy controls were recruited for this study. The demographics and clinical characteristics are shown in Table 1. Healthy controls were matched for age, gender and body mass index (BMI) (Table 1). One participant with sarcoidosis (active cardiac disease) and one healthy control (FEV1 < 60% predicted) were excluded. A greater proportion of participants with sarcoidosis were of black Afro-Caribbean ethnicity compared to controls (Table 1). No participants had a clinical diagnosis of anxiety or depression.

Physical Activity Monitoring

Participants with sarcoidosis reported they were adherent with objective physical activity monitoring; only one participant (healthy control) reported non-adherence for more than 8 h for 2 days. Data from these 2 days for this participant was not included in the analysis. Physical activity data are summarised in Fig. 1.
Table 1  Demographic and clinical characteristics of the study participants

| Characteristics                          | Healthy controls (n = 14) | Sarcoïdosis (n = 15) |
|-----------------------------------------|---------------------------|-----------------------|
| Age (years)                             | 46.5 (5.5)                | 52.7 (15.5)           |
| Female (n, %)                           | 10 (71)                   | 11 (73)               |
| BMI (kg/m²)                             | 27.1 (4.1)                | 27.7 (4.4)            |
| Ethnicity (n, %)                        |                           |                       |
| Caucasian                               | 10 (71)                   | 3 (20)                |
| Afro-Caribbean                          | 1 (7)                     | 9 (60)                |
| Other                                   | 3 (21)                    | 3 (20)                |
| Smoking status (n, %)                   |                           |                       |
| Current                                 | 0 (0)                     | 1 (7)                 |
| Ex-smoker                               | 4 (29)                    | 4 (27)                |
| Never                                   | 10 (71)                   | 10 (67)               |
| Time since diagnosis (years)            | 8.3 (8.4)                 |                       |
| Organ involvement                      | N/A                       |                       |
| Lungs                                   | 15 (100)                  |                       |
| Skin                                    | 6 (40)                    |                       |
| Eyes                                    | 3 (20)                    |                       |
| Other                                   | 8 (53)                    |                       |
| Multiple organ involvement              | N/A                       |                       |
| ≥2                                      | 12 (80)                   |                       |
| ≥3                                      | 5 (33)                    |                       |
| Scadding stage                          | N/A                       |                       |
| 0                                       | 0 (0)                     |                       |
| 1                                       | 4 (27)                    |                       |
| 2                                       | 3 (20)                    |                       |
| 3                                       | 4 (27)                    |                       |
| 4                                       | 4 (27)                    |                       |
| Pulmonary function                      |                           |                       |
| FEV₁ % predicted                        | 98.1 (14.7)               | 65.7 (18.6)*          |
| FVC % predicted                         | 107.3 (17.0)              | 78.5 (17.7)*          |
| FEV₁/FVC                                | 75.9 (6.1)                | 69.1 (12.6)*          |
| T_LCO% predicted                        | 86.8 (7.0)                | 58.4 (13.8)*          |
| ACE (IU/L)                              | N/A                       | 54 (28)               |
| Immunosuppressant                       | N/A                       |                       |
| None                                    | 5 (33)                    |                       |
| Prednisolone                            | 10 (67)                   |                       |
| Methotrexil                             | 3 (20)                    |                       |
| Azathioprine                            | 1 (7)                     |                       |
| Hydroxychloroquine                      | 2 (14)                    |                       |
| Inhaled corticosteroid                  | 2 (14)                    |                       |
| MRC dyspnoea score                      | 1 (1)                     | 3 (1)                 |
| FAS                                     | 15 (4)                    | 23 (7)                |
| KSQ                                     | N/A                       |                       |

Data presented as mean (SD) or absolute number (%). Immunosuppressants were those prescribed at the time of the study.

BMI body mass index; MRC Medical Research Council; ACE angiotensin-converting enzyme; FEV₁ forced expiratory volume in 1 s; FVC forced vital capacity; T_LCO diffusion capacity of lung for carbon monoxide; FAS Fatigue Assessment Scale; KSQ King’s Sarcoidosis Questionnaire.

* p < 0.05

Fig. 1 Physical activity in participants with sarcoidosis and healthy controls.

Fig. 2 A comparison of physical activity (steps) between participants with sarcoidosis and healthy controls on a daily step counts and b daily stepping time.
Step Count and Stepping Time

Daily step counts were significantly lower in participants with sarcoidosis as compared to healthy controls; mean (SD) 5624 (1875) versus 10,429 (29,422) steps, respectively, mean difference (95% CI) 4804 (2888–6720) steps, \( p < 0.001 \) (Fig. 2a; Table 2). Daily stepping time was also significantly lower in participants with sarcoidosis than in healthy controls; mean (SD) 1.18 (0.35) versus 1.97 (0.46) h/day, respectively, mean difference (95% CI) 0.78 (0.47–1.10), \( p < 0.001 \) (Fig. 2b; Table 2).

Sit-to-Stand Transitions and Standing Time

There was a trend towards a lower number of sit-to-stand transitions in participants with sarcoidosis than in healthy controls; median (IQR) 53.0 (35.0–59.0) versus 63 (47–69) transitions/day, respectively, mean difference (95% CI) 7.8 (0.47–1.10), \( p = 0.095 \). There was no significant difference in the time spent standing between participants with sarcoidosis than in healthy controls; median (IQR) of 4.16 (2.86–6.27) versus 3.77 (3.48–4.60) h/day respectively, \( p = 0.915 \) (Table 2).

Association Between Physical Activity and Clinical Characteristics

There was no significant association between mean daily step count and age \( (r = -0.43, p = 0.107) \), BMI \( (r = 0.06, p = 0.842) \), Scadding Chest X-ray staging \( (\rho = -0.35, p = 0.202) \), number of organs involved \( (\rho = 0.23, p = 0.410) \) or use of corticosteroids \( (\rho = 0.17) \). There was a trend towards an association between number of organs involved and daily standing time \( (\rho = -0.47, p = 0.082) \).

Exercise Capacity (6MWT)

The 6-min walking distance (6MWD) was significantly lower in participants with sarcoidosis compared to healthy controls; mean (SD) 375 (59) versus 487 (92) metres; mean difference (95% CI) 112 (52, 172) metres, \( p < 0.001 \) (Fig. 3). There was a significant correlation between 6MWD and the

---

**Table 2** Objective and subjective assessments of physical activity in participants with sarcoidosis and healthy controls

|                          | Healthy controls \((n = 14)\) | Sarcoidosis \((n = 15)\) |
|--------------------------|-------------------------------|--------------------------|
| **Objective assessments**|                               |                          |
| 6MWD (m)                 | 487 (92)                      | 375 (59)*                |
| **Physical activity**    |                               |                          |
| Step counts (/day)       | 10,429 (29,422)              | 5624 (1875)†             |
| Sit to stand transitions (/day) | 63 (47–69) | 53 (35–59)               |
| Upright time (h/day)     | 5.69 (5.26–6.47)             | 5.71 (3.73–7.56)         |
| Stepping time (h/day)    | 1.86 (1.73–2.23)             | 1.17 (0.99–1.55)†        |
| Standing time (h/day)    | 3.77 (3.48–4.60)             | 4.16 (2.86–6.27)         |
| **Subjective assessments**|                               |                          |
| IPAQ scores              |                               |                          |
| Overall (MET-min/week)   | 3230 (1912–5599)             | 2153 (1152–4925)         |
| Walking (MET-min/week)   | 1287 (412–1914)              | 1386 (330–3366)          |
| Moderate PA (MET-min/week)| 840 (210–1510) | 320 (127–2175)          |
| Vigorous PA (MET-min/week)| 480 (0–3360) | 0 (0–0)†                |

Data presented as mean (SD) or median (IQR)

6MWD 6-min walk distance; IPAQ International Physical Activity Questionnaire; MET metabolic equivalent

\*\( p = 0.0009 \)

\†\( p < 0.0001 \)

\‡\( p = 0.017 \)
daily step count in participants with sarcoidosis ($r = 0.63$, $p = 0.011$; Fig. E1). There was a significant association between 6MWD and self-reported vigorous activity on IPAQ ($\rho = 0.52$, $p = 0.048$) and a trend to significance for the relationship between 6MWD and self-reported walking activity on IPAQ ($\rho = 0.48$, $p = 0.071$). There was no significant correlation between 6MWD and self-reported total physical activity on IPAQ ($\rho = 0.06$, $p = 0.829$).

**Lung Function**

There was no association between daily step count and lung function measures in participants with sarcoidosis (FEV$_1$: $r = 0.27$, $p = 0.330$; FVC: $r = 0.29$, $p = 0.294$; T$_{LCO}$: $r = -0.01$, $p = 0.963$). This was in contrast to healthy participants in which there were significant relationships (FEV$_1$: $r = 0.71$, $p = 0.007$; FVC: $r = 0.69$, $p = 0.009$; T$_{LCO}$: $r = 0.80$, $p = 0.001$). There was no significant association between lung function measures and daily stepping time in participants with sarcoidosis (FEV$_1$: $r = 0.17$; FVC: $r = 0.30$; T$_{LCO}$: $r = -0.11$), daily standing time (FEV$_1$: $r = -0.02$; FVC: $r = -0.18$; T$_{LCO}$: $r = -0.31$) or daily sit to stand transitions (FEV$_1$: $r = -0.17$; FVC: $r = -0.05$; T$_{LCO}$: $r = -0.03$), all $p > 0.05$.

**Subjective Assessments**

**International Physical Activity Questionnaire**

Vigorous physical activity was significantly lower in participants with sarcoidosis than in healthy controls; median (IQR) of 0 (0) versus 480 (0–3360) MET-min/week, respectively, $p = 0.017$ (Table 2). The majority of participants with sarcoidosis, 13 (87%), reported no vigorous activity in contrast to 7 (50%) healthy controls ($p < 0.01$). Participants with sarcoidosis reported lower overall physical activity compared to healthy controls but this was not statistically significantly different; median (IQR) 2153 (1152–4925) versus 3230 (1912–5599) MET-min/week, respectively, $p = 0.326$ (Table 2).

In participants with sarcoidosis, there was a significant association between walking activity on IPAQ and daily stepping time ($r = 0.61$, $p = 0.018$). There was a trend to significance for the relationship between walking activity (IPAQ) and daily step count ($r = 0.52$, $p = 0.052$). There was no association between IPAQ total score and objective daily step count ($r = 0.16$, $p = 0.594$).

**Fatigue: Fatigue Assessment Scale**

Participants with sarcoidosis reported more fatigue than healthy controls; mean (SD) FAS score 23.27 (6.70) versus 15.43 (3.65); mean difference (95% CI) 7.84 (3.72–11.96), $p < 0.001$ (Table E1). There was a significant relationship between fatigue (FAS) in sarcoidosis and the time spent upright per day measured with the accelerometer ($r = -0.63$, $p = 0.013$) and time spent standing per day ($r = -0.67$, $p = 0.006$; Fig. E2a). There was no significant association between fatigue and sit to stand transitions in participants with sarcoidosis ($r = -0.01$, $p = 0.973$) or daily step counts ($r = 0.04$, $p = 0.884$). Fatigue was not associated with self-reported overall IPAQ physical activity ($p = 0.28$, $p = 0.325$) in participants with sarcoidosis (Table E1). For healthy controls, there was no significant correlation between fatigue and objective assessments of physical activity ($p = -0.03$ to 0.15, all $p > 0.05$).

**MRC Dyspnoea**

Participants with sarcoidosis reported mean (SD) MRC dyspnoea score 3.0 (1). There was a significant correlation between MRC dyspnoea scores and the number of sit to stand transitions ($r = -0.53$, $p = 0.044$). There was also a trend towards significance in the relationship between the MRC dyspnoea scores and daily step counts in participants with sarcoidosis ($r = -0.47$, $p = 0.080$).

**Health Status: King's Sarcoidosis Questionnaire**

The health status of the participants with sarcoidosis measured with the KSQ was moderate to severely impaired (Table 1). There were significant correlations between the KSQ Lung scores and time spent standing per day ($r = 0.58$, $p = 0.023$; Fig. E2b) and time spent upright ($r = 0.52$, $p = 0.045$). There was no significant association between KSQ Lung scores and daily step count ($p = 0.484$), daily stepping time ($p = 0.611$) and sit to stand transitions ($p = 0.850$). There was no significant correlation between KSQ General Health scores and objective measures of physical activity ($r = -0.38$ to 0.42, $p = 0.115–0.262$). There was a significant association between the self-reported overall physical activity (IPAQ scores) and the KSQ lung domain ($r = -0.56$, $p = 0.042$; Table E1).

**Discussion**

This is the first study to objectively assess physical activity in sarcoidosis with a validated triaxial accelerometer [19–22]. Physical activity was significantly reduced in patients with sarcoidosis compared to healthy controls. The 6-min walk test had the strongest association with physical activity in patients with sarcoidosis. Surprisingly, there was no significant association between daily step counts and fatigue. Fatigue was, however, associated with reduced time...
spent upright. There was no association between lung function measures and physical activity in sarcoidosis.

We investigated different types of physical activity in sarcoidosis made possible by utilising a triaxial accelerometer [19–22]. Daily step counts and daily stepping time were reduced in patients with sarcoidosis compared with healthy controls. Participants with sarcoidosis spent less time walking and had a lower cadence (steps/minute) compared to healthy controls. Self-reported physical activity was lower in patients with sarcoidosis compared with healthy controls, but the difference was not statistically significant. Self-assessed physical activity is known to correlate poorly with objective measures [34]. Self-reported vigorous physical activity was, however, significantly reduced in patients with sarcoidosis. Furthermore, objective daily step counts correlated better with self-reported IPAQ walking activity compared to IPAQ overall activity which reflects a wide range of daily activities, many of which do not involve walking. The 6MWT had the strongest association with physical activity of all clinical outcome measures assessed, similar to findings in patients with interstitial lung disease and sarcoidosis [8, 9, 18]. The correlation between 6MWD and physical activity was moderate, suggesting that measures of exercise capacity do not fully capture physical activity. There was a trend towards an association between dyspnoea and daily step counts and sit-to-stand transitions. There was, however, no association between daily step counts and lung function or health-related quality of life. Health-related quality of life and dyspnoea were, however, associated with reduced time spent upright.

Fatigue is a common and troublesome symptom of sarcoidosis [6, 35, 36]. We found no association between daily step counts and fatigue, consistent with the findings of Bahmer et al. [18]. However, fatigue was associated with reduced time spent upright, and therefore, the impact of fatigue may be limited to specific types of physical activity. The reason for reduced physical activity in sarcoidosis is unclear. Physical activity parameters were not related to age, BMI, disease severity or medication use. The lack of clear associations with individual factors suggests that there may be multi-factorial reasons for reduced physical activity. The factors potentially relevant include cardiac function, psychological and medications [17, 37, 38]. The mechanisms of reduced physical activity in sarcoidosis should be studied further.

There are some limitations to our study. We investigated a small number of patients, and therefore, our findings need to be replicated in a larger study. Physical activity was assessed over 1 week, and this interval may have been too short to be representative of habitual physical activity. Some patients were taking treatments such as corticosteroids though it has been demonstrated that the use of corticosteroids does not affect muscle strength [4]. We did not find a significant difference in physical activity between those patients taking corticosteroids and no medications. There were differences in ethnicity between patients and healthy controls which may have biased our results. Our sample size was too small to analyse for any differences between ethnic groups. We did not assess the level of education and occupation of subjects and its impact on activity. Marshall et al. demonstrated that social class moderates the relationship between ethnicity and physical activity, and suggested that a focus on ethnicity in physical activity detracts from the significant role played by social classes [39]. It is possible that the control group may have been motivated to participate in an activity study and, therefore, were physically fit. Future studies using a matched case-control design can overcome this potential bias.

In conclusion, physical activity is reduced in patients with sarcoidosis compared with healthy controls. The assessment of physical activity was well tolerated. Physical activity monitors can provide a unique assessment of the impact of disease on function that is not captured by existing clinical outcome measures for sarcoidosis, and can potentially be used to assess response to therapy. The mechanism for reduced physical activity in sarcoidosis is unclear but is likely to be multi-factorial and needs further study.

Acknowledgements We thank Tracey Fleming, Lynne Morgan, and the staff of the Chest Unit for their assistance for the study. We thank all patients and volunteers for their participation.

Author Contributions Conception and design: SB, MM, SV; Participants screening: SV, SCM; Study recruitment: SV, SCM, CW; Data analysis: PC, SV, MM, SB; Drafting manuscript: SB, PC; Interpretation and revised manuscript: SB, PC, MM, CJ, AS, SV, SCM.

Compliance with Ethical Standards

Conflict of interest None to be declared.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Baughman RP, Culver DA, Judson MA (2011) A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 183:573–581
2. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J (2014) Sarcoidosis. Lancet 383:1155–1167
3. Marcellis RJ, Lenssen AF, Drent M, De Vries J (2012) Association between physical activity and quality of life in sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis 46:1–12
4. Marcellis RGJ, Lenssen AF, Elferich MDP, De Vries J, Kassim S, Foerster K, Drent M (2011) Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J 38:628–634

5. Kallianos A, Zoragoulidi P, Ampatzoglou F, Trakada G, Gialafos E, Pitsiou G, Patakis A, Veletza L, Zoragoulidis K, Hohenforst-Schmidt W, Petrides D, Kioumis I, Rapti A (2015) Reduction of exercise capacity in sarcoidosis in relation to disease severity. Patient Prefer Adherence 9:1179–1188

6. Drent M, Lower EE, De Vries J (2012) Sarcoidosis-associated fatigue. Eur Respir J 40:255–263

7. Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, Korducki L, Hamilton A (2016) Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open 6:1–9

8. Wallaert B, Monge E, Le Rouzic O, Wémeau-Stervinou L, Saleron J, Grosbois JM (2013) Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest 144:1652–1658

9. Nakayama M, Bando M, Araki K, Sekine T, Kurosaki F, Sawata T, Nakazawa S, Mato N, Yamawasa H, Sugiyama Y (2015) Physical activity in patients with idiopathic pulmonary fibrosis. Respirology 20:640–646

10. Gimeno-Santos E, Frei A, Steurer-Stey C, De Battle J, Rabinovich RA, Raste Y, Hopkinson NS, Polkey MI, van Remoortel H, Troosters T, Kulich K, Karlsson N, Puhan MA, Garcia-Aymerich J, Garcia-Aymerich J (2014) Determinants and outcomes of physical activity in patients with COPD: a systematic review. Thorax 69:731–739

11. Vasudevan S, Maddocks M, Chamberlain S, Spinou A, Wood C, Jolley CJ, Birring SS (2013) P197 physical activity in sarcoidosis. Thorax 68:A165–A165

12. Van Remoortel H, Giavedoni S, Raste Y, Burtin C, Louvaris Z, Gimeno-Santos E, Langer D, Glendenning A, Hopkinson NS, Vogiatzis I, Peterson BT, Wilson F, Mann B, Rabinovich R, Puhan MA, Troosters T (2012) Validity of activity monitors in chronic and chronic disease: a systematic review. Int J Behav Nutr Phys Act 9:84

13. Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, De Jong C, Rabinovich RA, Hopkinson NS, Polkey MI, Vogiatzis I, Tabberer M, Dobbs F, Iannov N, De Boer WI, Van Der Molen T, Kulich K, Serra I, Basagaña X, Troosters T, Puhan MA, Karlsson N, Garcia-Aymerich J, Corriol-Rohou S, Jarrott J, Erzen D, Brindicci C, Higenbottam T, Sciri M, McBrude P, Kamel N, De Boer P et al (2015) The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J 46:988–1000

14. Watz H, Waschki B, Meyer T, Magnussen H (2009) Physical activity in patients with COPD. Eur Respir J 33:262–272

15. Donaire-Gonzalez D, Gimeno-Santos E, Ballesta E, Rodriguez DA, Farrero E, De Battle J, Benet M, Ferrer A, Barberà JA, Gea J, Rodriguez-Roisin R, Antó JM, Garcia-Aymerich J (2013) Physical activity in COPD patients: patterns and bouts. Eur Respir J 42:993–1002

16. Troosters T, Sciriha F, Battaglia S, Langer D, Valluri SR, Martino L, Benzo R, Andre D, Weissman I, Decramer M (2010) Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 104:1005–1011

17. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, López-Collazo E, Alvarez-Sala R (2009) Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 180:506–512

18. Bahmer T, Watz H, Develaska M, Waschki B, Rabe KF, Magnussen H, Kirsten D, Kirsten A-M (2017) Physical activity and fatigue in patients with sarcoidosis. Respiration 95(1):18–26

19. Maddocks M, Petrou A, Skipper L, Wilcock A (2010) Validity of three accelerometers during treadmill walking and motor vehicle travel. Br J Sport Med 44:606–608

20. Cindy Ng LW, Jenkins S, Hill K (2012) Accuracy and responsiveness of the stepwatch activity monitor and ActivPAL in patients with COPD when walking with and without a rollerator. Disabil Rehabil 34:1317–1322

21. Harrington DM, Welk GJ, Donnelly AE (2011) Validation of MET estimates and step measurement using the ActivPAL physical activity logger. J Sports Sci 29:627–633

22. Ryan CG, Grant PM, Tighe WW, Granat MH, Ryan CG (2006) The validity and reliability of a novel activity monitor as a measure of walking. Br J Sport Med 40:779–784

23. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager HJ (1999) Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffus Lung Dis 16:75–86

24. Scadding JG (1961) Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years’ observation. Br Med J 2:1165–1172

25. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P (2003) International physical activity questionnaire: 12-Country reliability and validity. Med Sci Sports Exerc 35:1381–1395

26. De Vries J, Michielsen H, Van Heck GL, Drent M (2004) Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol 9:279–291

27. Michielsen HJ, De Vries J, Van Heck GL, Van de Vijver FJ, Sijsma K (2004) Examination of the dimensionality of fatigue. Eur J Psychol Assess 20:39–48

28. Fletcher CM (1952) The clinical diagnosis of pulmonary emphysema: an experimental study. Proc R Soc Med 45:577–584

29. Patel AS, Siegert RJ, Creamer D, Larkin G, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS (2013) The development and validation of the King’s Sarcoidosis Questionnaire for the assessment of health status. Thorax 68:57–65

30. Baughman RP, Swess N, Keijzers R, Birring SS, Shipley R, Saketkoo LA, Lower EE (2017) Repository corticortopin for chronic pulmonary sarcoidosis. Lung 195(3):313–322

31. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wagner J, De Vries J, Michielsen H, Van Heck GL, Drent M (2005) Standardisation of spirometry. Eur Respir J 26:319–338

32. Association for Respiratory Technology and Physiology (ARTP) (2013) A guide to performing quality assured diagnostic spirometry. Association for Respiratory Technology and Physiology (ARTP), Lichfield

33. Holland AE, Spruit MA, Troosters T, Pepin V, Saey D, McCormack MC, Carlin BW, Sciurba FC, Pitta F, Wanger J, MacIntyre N, Kaminsky DA, Culver BH, Revill SM, Hernandez NA, Andrianopoulos V, Camillo CA, Mitchell KE, Lee AL, Hill CJ, Singh SJ (2014) An official European respiratory society/American thoracic society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 44:1428–1446

34. Lee PH, Macfarlane DJ, Lam T, Stewart SM (2011) Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act 8:115

35. Aggarwal AN, Sahu KK, Gupta D (2016) Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral corticosteroids. Sarcoidosis Vasc Diffus Lung Dis 33:124–129
36. Strookappe B, De Vries J, Elfferich M, Kuijpers P, Kneevel T, Drent M (2016) Predictors of fatigue in sarcoidosis: the value of exercise testing. Respir Med 116:49–54

37. Nguyen HQ, Fan VS, Herting J, Lee J, Fu M, Chen Z, Borson S, Kohen R, Matute-Bello G, Pagalilauan G, Adams SG (2013) Patients with COPD with higher levels of anxiety are more physically active. Chest 144:145–151

38. Garcia-Aymerich J, Félez MA, Escarrabill J, Marrades RM, Morera J, Elosua R, Antó JM (2004) Physical activity and its determinants in severe chronic obstructive pulmonary disease. Med Sci Sports Exerc 36:1667–1673

39. Marshall SJ, Jones DA, Ainsworth BE, Reis JP, Levy SS, Macera CA (2007) Race/ethnicity, social class, and leisure-time physical inactivity. Med Sci Sports Exerc 39:44–51

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.